Cross-ethnic evaluation of gut microbial signatures reveal increased colonization with oral pathobionts in the north Indian inflammatory bowel disease cohort [0.03%]
跨种族评估肠道微生物标志物显示北印度炎症性肠病队列中口腔致病共生菌定植增加
Arshdeep Singh,Garima Juyal,Ranko Gacesa et al.
Arshdeep Singh et al.
Background/aims: Inflammatory bowel disease (IBD) has become a global health concern. With the growing evidence of the gut microbiota's role in IBD, studying microbial compositions across ethnic cohorts is essential to id...
Efficacy and safety of carotegrast methyl in active ulcerative colitis: a real-world prospective cohort study [0.03%]
甲基卡罗替斯特治疗活动性溃疡性结肠炎疗效及安全性的真实世界前瞻性队列研究
Takahiro Shimoyama,Takayuki Yamamoto,Haruka Miyao et al.
Takahiro Shimoyama et al.
Background/aims: Carotegrast methyl, an oral α4-integrin inhibitor, was recently approved for the treatment of active ulcerative colitis (UC). However, real-world data regarding its efficacy and safety remain scarce. Thi...
Week 2 remission with vedolizumab as a predictor of long-term remission in patients with ulcerative colitis: a multicenter, retrospective, observational study [0.03%]
维多珠单抗诱导第2周缓解可预测溃疡性结肠炎患者长期缓解：一项基于多中心回顾性观察研究的结果
Taku Kobayashi,Tadakazu Hisamatsu,Satoshi Motoya et al.
Taku Kobayashi et al.
Background/aims: Vedolizumab (VDZ), a gut-selective monoclonal antibody for ulcerative colitis (UC) treatment, has no established biomarkers or clinical features that predict long-term remission. Week 2 remission, a poten...
Ulcerative colitis disease severity affects the speed of symptom relief under filgotinib treatment: a post hoc analysis of the phase 2b/3 SELECTION study [0.03%]
溃疡性结肠炎疾病严重程度影响filgotinib治疗下症状缓解速度：SELECTION研究的事后分析
Masayuki Saruta,Silvio Danese,Yoshie Takatori et al.
Masayuki Saruta et al.
Background/aims: Filgotinib is an oral, once-daily, Janus kinase 1 preferential inhibitor approved for the treatment of ulcerative colitis (UC). This study aimed to assess symptomatic response with filgotinib 200 mg (FIL2...
A real-world comparison of subcutaneous to intravenous administration of infliximab in patients with inflammatory bowel disease [0.03%]
真实世界中评估抗肿瘤坏死因子药物英夫利西单抗在炎症性肠病患者中的皮下注射和静脉输注的比较研究
Kwang Woo Kim,Hyoun Woo Kang,Seong-Joon Koh et al.
Kwang Woo Kim et al.
Background/aims: We compared intravenous and subcutaneous infliximab (IFX) as treatment for inflammatory bowel disease (IBD). Methods: ...
Evolution of inflammatory bowel disease in Korea: a 60-year perspective on clinical and research development [0.03%]
从临床和研究发展的角度透视韩国炎症性肠病的60年变迁
Suk-Kyun Yang
Suk-Kyun Yang
Inflammatory bowel disease (IBD) was once considered rare in Korea, with the first reported case documented in 1961. Since then, its incidence and prevalence have increased markedly, accompanied by significant progress in clinical care and ...
Comparative effectiveness of ustekinumab versus infliximab in the management of perianal fistulizing Crohn's disease: a retrospective study in China [0.03%]
乌司奴单抗与英夫利西单抗治疗肛周瘘管型克罗恩病的疗效比较：一项中国回顾性研究
Mengqi Chen,Zihan Chen,Jianming Lin et al.
Mengqi Chen et al.
Background/aims: Ustekinumab (UST) and infliximab (IFX) are both effective in the treatment of perianal fistulizing Crohn's disease (CD), but limited research has focused on comparing the efficacy of UST versus IFX in thi...
Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn's disease [0.03%]
乌帕替尼联合 Vedolizumab 治疗难治性溃疡性结肠炎和克罗恩病的疗效
Robert Gilmore,Amrutha Murali,Amirah Etchegaray et al.
Robert Gilmore et al.
Background/aims: Inflammatory bowel disease (IBD) is characterised by chronic inflammation of the gastrointestinal tract, and encompasses both ulcerative colitis (UC) and Crohn's disease (CD). Refractory disease is common...
Clinical spectrum of acute severe ulcerative colitis in the biologic era: a prospective cohort study from India [0.03%]
生物制剂时代急性重症溃疡性结肠炎的临床谱系：一项印度前瞻性队列研究
Arshdeep Singh,Mayur Luthra,Arshia Bhardwaj et al.
Arshdeep Singh et al.
Background/aims: Acute severe ulcerative colitis (ASUC) is a time-critical situation requiring urgent intervention. Limited data exist on the evolving clinical spectrum of ASUC in the era of advanced therapies. ...
The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective study [0.03%]
溃疡性结肠炎患者先前使用抗肿瘤坏死因子药物的时长与维多珠单抗疗效的相关性：一项真实世界多中心回顾性研究
Taku Kobayashi,Tadakazu Hisamatsu,Satoshi Motoya et al.
Taku Kobayashi et al.
Background/aims: Previous literature suggests that the response of patients with ulcerative colitis to vedolizumab may be affected by previous biologic therapy exposure. This real-world study evaluated vedolizumab treatme...